Association of CFU-F presence with alloSCT-related factors and with remission status at time of BM aspirate in the cohort of patients receiving alloSCT
. | CFU-F present N (%) . | No CFU-F present N (%) . | P value . |
---|---|---|---|
Disease status at time of alloSCT | .50 | ||
CR | 58 (42.3) | 23 (47.9) | |
Non CR | 79 (57.7) | 25 (52.1) | |
Conditioning regimen | .22 | ||
MAC | 22 (15.8) | 12 (23.5) | |
RIC or NMA | 117 (84.2) | 39 (76.5) | |
Use of ATG | .07 | ||
Yes | 116 (84.1) | 37 (72.5) | |
No | 22 (15.9) | 14 (27.5) | |
GvHD-prophylaxis | .21 | ||
CNI + MMF | 104 (78.8) | 35 (70.0) | |
CNI + MTx | 28 (21.2) | 15 (30.0) | |
Remission at BM aspirate | .76 | ||
CR | 120 (84.5) | 43 (82.7) | |
Non CR | 22 (15.5) | 9 (17.3) | |
Chimerism at BM aspirate | .047 | ||
100% donor | 104 (80.0) | 28 (65.1) | |
Persisting recipient fraction | 26 (20.0) | 15 (34.9) |
. | CFU-F present N (%) . | No CFU-F present N (%) . | P value . |
---|---|---|---|
Disease status at time of alloSCT | .50 | ||
CR | 58 (42.3) | 23 (47.9) | |
Non CR | 79 (57.7) | 25 (52.1) | |
Conditioning regimen | .22 | ||
MAC | 22 (15.8) | 12 (23.5) | |
RIC or NMA | 117 (84.2) | 39 (76.5) | |
Use of ATG | .07 | ||
Yes | 116 (84.1) | 37 (72.5) | |
No | 22 (15.9) | 14 (27.5) | |
GvHD-prophylaxis | .21 | ||
CNI + MMF | 104 (78.8) | 35 (70.0) | |
CNI + MTx | 28 (21.2) | 15 (30.0) | |
Remission at BM aspirate | .76 | ||
CR | 120 (84.5) | 43 (82.7) | |
Non CR | 22 (15.5) | 9 (17.3) | |
Chimerism at BM aspirate | .047 | ||
100% donor | 104 (80.0) | 28 (65.1) | |
Persisting recipient fraction | 26 (20.0) | 15 (34.9) |
For each patient, only the last available BM aspirate after alloSCT was included to avoid bias of repeated aspirates. Comparison was performed univariately using χ2 test.
ATG, anti-thymocyte globuline; CNI, calcineurin inhibitor (cyclosporine A or tacrolimus); CR, complete remission; MAC, myeloablative conditioning; MMF, mycophenolate; MTx, methotrexate; NMA, nonmyeloablative conditioning; RIC, reduced intensity conditioning.